SCHEMBL7542463

SCHEMBL7542463

Cc1cc(NS(=O)(=O)c2cc(C)c3c(c2)oc(=O)n3CCN2CCOCC2)ccc1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
PKM P14618 7/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
BRD4 O60885 2/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.42
TSHR P16473 1/20 0.42
MAPT P10636 3/20 0.42
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
GAA P10253 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7536067 0.84 PKM (0.48) PKMMEN1KMT2ASMN1; SMN2BRD4
SCHEMBL7541972 0.84 PKM (0.48) CYP3A4CYP2D6CYP2C19PKMMEN1
SCHEMBL7541742 0.81 PKM (0.60) PKMMEN1KMT2ASMN1; SMN2BRD4
SCHEMBL7537514 0.76 EGFR (0.49) PKMMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7542465 0.76 PKM (0.46) PKMMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7544040 0.76 PKM (0.49) PKMMEN1KMT2ASMN1; SMN2BRD4
SCHEMBL18306665 0.76 PKM (0.53) PKMMEN1KMT2ASMN1; SMN2BRD4
SCHEMBL7541685 0.73 PKM (0.52) PKMMEN1KMT2ASMN1; SMN2BRD4
SCHEMBL7536103 0.73 PKM (0.57) PKMMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7543649 0.71 PKM (0.60) PKMMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
EP-2427441-B1 PKM2 ACTIVATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS INC (US) 2016-12-14 EP disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
WO-2013056153-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE KUNG CHARLES (US) 2013-04-18 WO disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed
WO-2010129596-A1 PMK2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER PDK2, PDK1, PDK3 CYP3A4 1423/4885CYP2D6 1768/4885CYP2C19 2590/4885
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 CYP3A4 4630/4885CYP2D6 4580/4885CYP2C19 4798/4885
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 CYP3A4 4630/4885CYP2D6 4580/4885CYP2C19 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.